TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24029053

Group type: EXPERIMENTAL
Intervention: 2-[fluorine-18]fluoro-2-deoxy-(D)-glucose (FDG) PET scans in hyperthyroid patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (30 participants)
Number of subjects: 48
Study: 21334402

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3 levels
Number of subjects: 189
Study: 19326982

Group type: EXPERIMENTAL
Intervention: 3‐T MR imaging
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1.5‐T MR imaging
Number of subjects: 26
Study: 17384435

Group type: EXPERIMENTAL
Intervention: LY518674 (25 microg)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: LY518674 (100 microg)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: LY518674 (50 microg)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: LY518674 (10 microg)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Atorvastatin (10 or 40 mg) + LY518674
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: LY518674 (50 microg and 100 microg)
Number of subjects: 613
Study: 15163444

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11176963

Group type: EXPERIMENTAL
Intervention: ABT-431 (5, 10, 20, and 40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 20
Study: 9483595

Group type: EXPERIMENTAL
Intervention: Air (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 65% N2O, oxygen and halothane (Group B)
Number of subjects: 52
Study: 7915067

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg/1 min bolus, followed by 0.2 mg/kg/min infusion)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gallopamil (0.025 mg/kg/3 min)
Number of subjects: 14
Study: 2968052

Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion at 10 pmol.kg‐1.min‐1 for 1 hour
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion (vehicle)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: alpha-hANP infusion in normal volunteers
Number of subjects: 14
Study: 29778565

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (400/600 kcal on two non-consecutive days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Continuous energy restriction
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Number of subjects: 112
Study: 28521967

Group type: EXPERIMENTAL
Intervention: +PD (with pterygomaxillary disjunction)
Number of subjects: 25

Group type: COMPARATOR
Intervention: -PD (without pterygomaxillary disjunction)
Number of subjects: 25
Study: 25166455

Group type: EXPERIMENTAL
Intervention: Individualized self-management (ISM) support
Number of subjects: 170

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 170
Study: 24074932

Group type: EXPERIMENTAL
Intervention: Passively scattered proton therapy (PSPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intensity modulated photon therapy (IMRT)
Number of subjects: 20
Study: 20675936

Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonate treatment for Osteogenesis Imperfecta
Number of subjects: 0
Study: 18794653

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 38
Study: 16124952

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin and UFH
Number of subjects: 0
Study: 12667386

Group type: EXPERIMENTAL
Intervention: Oseltamivir phosphate, 75 mg twice daily for 5 days
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478

Group type: COMPARATOR
Intervention: Oseltamivir phosphate and Placebo
Number of subjects: 478
Study: 10665159

Group type: EXPERIMENTAL
Intervention: Therapist-guided self-help
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unguided self-help
Number of subjects: 40
Study: 8625237

Group type: EXPERIMENTAL
Intervention: FAC (5-fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTC (5-fluorouracil, cyclophosphamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAC and FTC
Number of subjects: 0
Study: 1805068

Group type: EXPERIMENTAL
Intervention: Acediprol (sodium valproate)
Number of subjects: 37
Study: 7408415

Group type: EXPERIMENTAL
Intervention: Heparin (50 U intravenously)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cumulative doses of heparin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heparin (400 U intravenously of Harris LO14)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heparin (small doses)
Number of subjects: 8
Study: 31495331

Group type: EXPERIMENTAL
Intervention: Intravenous allogeneic mesenchymal stem cells (1.5 million cells/kg body weight)
Number of subjects: 36
Study: 27723416

Group type: EXPERIMENTAL
Intervention: Yoga intervention (1 hour of yoga before dinner for 5 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study: 25735605

Group type: EXPERIMENTAL
Intervention: Great Taste, Less Waste (GTLW) communications campaign
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Foods 2 Choose (F2C) nutrition-only campaign
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 582
Study: 23963894

Group type: EXPERIMENTAL
Intervention: 6-month hypocaloric diet (reduced carbohydrates or reduced fat content)
Number of subjects: 50
Study: 21296325

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty
Number of subjects: 509

Group type: COMPARATOR
Intervention: Groups based on PASP levels
Number of subjects: 509
Study: 19005465

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 17729010

Group type: EXPERIMENTAL
Intervention: Local intraarterial thrombolysis with recombinant tissue-type plasminogen activator (rtPA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous anticoagulation using i.v. heparin infusion
Number of subjects: 16
Study: 15132725

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg/day (low dose group)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/day (high dose group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 101
Study: 11463679

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic interpersonal therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 119
Study: 9875644

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study: 7739439

Group type: EXPERIMENTAL
Intervention: Antibiotic added to sterile physiologic solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Through drainage with sterile physiologic solution
Number of subjects: 33
Study: 2918157

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg followed by 0.35 mg/kg body weight)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 54
Study: 163386

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 gm three times a day for nine months, plus 3 gm daily at onset of cold)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Lactose placebo (three times a day for nine months, plus placebo at onset of cold)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 311
Study: 31175566

Group type: EXPERIMENTAL
Intervention: Educational and training experiential intervention (ETEI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet and nutrition education (Control)
Number of subjects: 25
Study: 31152541

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/d
Number of subjects: 273

Group type: COMPARATOR
Intervention: 800 IU vitamin D3/d
Number of subjects: 273
Study: 28376373

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 25936298

Group type: EXPERIMENTAL
Intervention: 500 ml whipping cream (30% fat)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg l‐methionine
Number of subjects: 25
Study: 23104183

Group type: EXPERIMENTAL
Intervention: Facilitatory scene priming (scene primes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control primes
Number of subjects: 0
Study: 22071998

Group type: EXPERIMENTAL
Intervention: Formula-driven transfusion protocol (1 plasma:1 platelet:1 RBC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Laboratory-driven transfusion protocol
Number of subjects: 18
Study: 19927632

Group type: EXPERIMENTAL
Intervention: TNK-tPA
Number of subjects: 110

Group type: COMPARATOR
Intervention: rt-PA
Number of subjects: 110
Study: 17509903

Group type: EXPERIMENTAL
Intervention: Nitric oxide donation via a patch
Number of subjects: 3
Study: 15350490

Group type: EXPERIMENTAL
Intervention: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 24 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 48 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alpha‐interferon alone (historical data).
Number of subjects: 20
Study: 11722315

Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention plus general family support and standard care
Number of subjects: 79

Group type: COMPARATOR
Intervention: General family support and standard care
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention
Number of subjects: 79
Study: 9738086

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg per kilogram)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Phenobarbital (15 mg per kilogram)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg per kilogram) followed by Phenytoin (18 mg per kilogram)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Phenytoin (18 mg per kilogram)
Number of subjects: 518

Group type: COMPARATOR
Intervention: All treatments (Lorazepam, Phenobarbital, Diazepam plus Phenytoin, Phenytoin)
Number of subjects: 518
Study: 8062154

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy age-matched premenopausal women
Number of subjects: 0
Study: 2499830

Group type: EXPERIMENTAL
Intervention: Isotonic, isosmotic lavage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional three-day bowel preparation
Number of subjects: 0
Study: 4834974

Group type: EXPERIMENTAL
Intervention: Carbidopa plus 20% of previous levodopa dosage in fixed combination tablets (levodopa:carbidopa in a 10:1 ratio)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination tablets (levodopa:carbidopa in a 10:1 ratio)
Number of subjects: 20
Study: 31107348

Group type: EXPERIMENTAL
Intervention: RPE (rating of perceived exertion)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: RM (repetition maximum)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: %1RM (percent one repetition maximum)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: RiR (repetitions in reserve)
Number of subjects: 82
Study: 28279548

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 104
Study: 26829013

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Skills Training telephone counseling intervention
Number of subjects: 2151

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2151
Study: 25120316

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg/d
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg/d
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 22417191

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 101
Study: 19464611

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 5 L/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 10 L/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flushing with O(2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vital capacity breathing sessions
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 17485579

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 2114

Group type: EXPERIMENTAL
Intervention: Implanted cardioverter-defibrillators (ICDs)
Number of subjects: 2114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2114
Study: 16239356

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER (500 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin IR (250 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin IR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER and IR
Number of subjects: 0
Study: 12219247

Group type: EXPERIMENTAL
Intervention: Slimming liposomes (SLC) containing esculoside, Centella asiatica extracts, caffeine, and L-carnitine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slimming liposomes (SLC)
Number of subjects: 0
Study: 9568861

Group type: EXPERIMENTAL
Intervention: Ultrasound marking of the internal jugular vein before disinfection and local anaesthesia
Number of subjects: 65

Group type: COMPARATOR
Intervention: Real-time ultrasound guidance during cannulation
Number of subjects: 65
Study: 8749878

Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose betaxolol (20 mg once daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose diltiazem (90 mg twice daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose diltiazem and digoxin with low-dose betaxolol
Number of subjects: 35
Study: 2667399

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 1098671

Group type: EXPERIMENTAL
Intervention: Teoremac (420 mg/day for 14 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Indometacin (100 mg/day for 14 days)
Number of subjects: 39
Study: 31366226

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray combined with a newly initiated oral antidepressant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressant plus placebo
Number of subjects: 0
Study: 28530448

Group type: EXPERIMENTAL
Intervention: Beef
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbohydrate
Number of subjects: 24
Study: 25381345

Group type: EXPERIMENTAL
Intervention: Occupation-based approach using the iPad application, Aid for Decision-making in Occupation Choice.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Impairment-based approach focusing on patients' generic abilities and activities of daily living (ADL).
Number of subjects: 54
Study: 23579211

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 723

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 723
Study: 21364435

Group type: EXPERIMENTAL
Intervention: Obagi Nu‐Derm System
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care regimen
Number of subjects: 56
Study: 19472699

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 48
Study: 16936557

Group type: EXPERIMENTAL
Intervention: GS-9137 (200, 400, or 800 mg BID, 800 mg QD, or 50 mg+100 mg ritonavir QD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14505546

Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable capsule (BIFICO), 420 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 30
Study: 11533750

Group type: EXPERIMENTAL
Intervention: 200mg chromium/day as CrCL3
Number of subjects: 44
Study: 9491672

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC) estimated by polyethylene glycol precipitation (PEG pptn.) test and latex agglutination inhibition (LAI) test.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stage I genitourinary cancer patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stage II genitourinary cancer patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stage III genitourinary cancer patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stage IV genitourinary cancer patients
Number of subjects: 48
Study: 8238131

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 93

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 93
Study: 3911373

Group type: EXPERIMENTAL
Intervention: VBCMP
Number of subjects: 96

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 96

Group type: COMPARATOR
Intervention: MP
Number of subjects: 96
Study: 29437758

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Control (questionnaire only)
Number of subjects: 1030
Study: 26965429

Group type: EXPERIMENTAL
Intervention: Personalized e-therapy program in addition to usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 120
Study: 23764858

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST) 5 days/week at the highest tolerated load
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST)
Number of subjects: 16
Study: 23684832

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (lower or null increase of IFN-γ)
Number of subjects: 0
Study: 20947595

Group type: EXPERIMENTAL
Intervention: Bypass grafting plus transplantation of bone marrow‐derived stem cells
Number of subjects: 34

Group type: COMPARATOR
Intervention: Revascularization only (control group)
Number of subjects: 34
Study: 17981067

Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine (2.5 microg of each polysaccharide, 5 microg of each polysaccharide, or 2.5 microg of PRP and 5 microg each of MenA and MenC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed DTPw‐HBV and Hib or DTPw‐HBV/Hib and MenC conjugate vaccines
Number of subjects: 0
Study: 16148455

Group type: EXPERIMENTAL
Intervention: THC (1.8% and 3.6%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (no active cannabinoids)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: THC with varying concentrations of CBC (0.1% versus 0.5%) and CBD (0.2% versus 1.0%)
Number of subjects: 23
Study: 12942093

Group type: EXPERIMENTAL
Intervention: Fractionated TBI (fTBI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Busulphan
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Complete T cell donor chimerism
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: T cell mixed chimerism (MC)
Number of subjects: 180
Study: 10751812

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg kg(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pipecuronium (0.07 mg kg(‐1))
Number of subjects: 20
Study: 8835586

Group type: EXPERIMENTAL
Intervention: ICRC vaccine
Number of subjects: 368

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 368
Study: 1388120

Group type: EXPERIMENTAL
Intervention: Teicoplanin plus ciprofloxacin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gentamicin plus piperacillin
Number of subjects: 80
Study: 3965341

Group type: EXPERIMENTAL
Intervention: Vitamin A therapy, 50,000 U twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29534741

Group type: EXPERIMENTAL
Intervention: Comprehensive mental health care program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team intervention
Number of subjects: 0
Study: 27530379

Group type: EXPERIMENTAL
Intervention: PF-05280586
Number of subjects: 214

Group type: COMPARATOR
Intervention: rituximab-EU
Number of subjects: 214

Group type: COMPARATOR
Intervention: rituximab-US
Number of subjects: 214
Study: 24703319

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 211

Group type: COMPARATOR
Intervention: Non-bevacizumab treatment
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Bevacizumab with high tissue mRNA of angiogenic VEGF‐Axxxa
Number of subjects: 211
Study: 22522185

Group type: EXPERIMENTAL
Intervention: Leaning forward (associated with heightened urge to approach stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reclining (associated with less of an urge to approach stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leaning forward
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reclining
Number of subjects: 0
Study: 20453572

Group type: EXPERIMENTAL
Intervention: Empowerment Education Program (EEP)
Number of subjects: 48